Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P01222
UPID:
TSHB_HUMAN
Alternative names:
Thyroid-stimulating hormone subunit beta; Thyrotropin beta chain
Alternative UPACC:
P01222; B1AKP0; Q16163
Background:
The Thyrotropin subunit beta, also known as Thyroid-stimulating hormone subunit beta or Thyrotropin beta chain, plays a crucial role in thyroid structure and metabolism regulation. Its primary function is indispensable for maintaining normal thyroid gland function.
Therapeutic significance:
Linked to Hypothyroidism, congenital, non-goitrous, 4 (CHNG4), a condition marked by severe growth retardation and intellectual disability due to isolated thyrotropin deficiency, understanding the role of Thyrotropin subunit beta could lead to targeted therapies for this autosomal recessive disorder.